Company research
Avid Bioservices, Inc.
CIK 704562Updated Nov 16, 2026
Historical securities (2)
CDMOP · NASDAQ · equity · closed Apr 14, 2021CDMO · NASDAQ · equity · closed Feb 5, 2025CDMOP price & chart
This listing closed Apr 14, 2021. Live provider charts are shown only for current listings.
About the company
Avid Bioservices is a dedicated CDMO focused on development and CGMP manufacturing of biologics. The Company provides a comprehensive range of process development, CGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. With more than 30 years of experience producing biologics, Avid's services include CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing and regulatory submissions support. For early-stage programs the Company provides a variety of process development activities, including cell line development, upstream and downstream development and optimization, analytical methods development, testing and characterization. The scope of our services ranges from standalone process development projects to full development and manufacturing programs through commercialization. www.avidbio.com
In the news
No coverage from other publishers is available.
Financials
FY 2024 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 336,557,000Source | 450,785,000Source | 429,843,000Source | 265,510,000Source |
| Property, Plant and Equipment, NetUSD | 186,514,000Source | 164,410,000Source | 92,955,000Source | 37,455,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 38,106,000Source | 59,916,000Source | 126,166,000Source | 169,915,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 16,644,000Source | 14,826,000Source | 20,547,000Source | 18,842,000Source |
| Inventory, NetUSD | 30,375,000Source | 45,102,000Source | 26,062,000Source | 11,871,000Source |
| Assets, CurrentUSD | 104,002,000Source | 132,343,000Source | 180,023,000Source | 207,804,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 6,513,000Source | 2,111,000Source | 1,879,000Source | 1,064,000Source |
| Operating Lease, Right-of-Use AssetUSD | 41,157,000Source | 34,463,000Source | 36,806,000Source | 18,691,000Source |
| Other Assets, NoncurrentUSD | 4,884,000Source | 4,402,000Source | 4,627,000Source | 1,210,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 275,668,000Source | 265,665,000Source | 255,317,000Source | 187,774,000Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 64,000Source | 62,000Source | 62,000Source | 61,000Source |
| Additional Paid in CapitalUSD | 632,696,000Source | 615,841,000Source | 605,841,000Source | 637,534,000Source |
| Retained Earnings (Accumulated Deficit)USD | -571,871,000Source | -430,783,000Source | -431,377,000Source | -559,859,000Source |
| Stockholders' Equity Attributable to ParentUSD | 60,889,000Source | 185,120,000Source | 174,526,000Source | 77,736,000Source |
| Liabilities and EquityUSD | 336,557,000Source | 450,785,000Source | 429,843,000Source | 265,510,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 70,566,000Source | 228,308,000Source | 75,761,000Source | 70,936,000Source |
| Operating Lease, Liability, CurrentUSD | 1,354,000Source | 3,024,000Source | 2,969,000Source | 1,355,000Source |
| Accounts Payable, CurrentUSD | 20,667,000Source | 36,392,000Source | 9,504,000Source | 9,257,000Source |
| Operating Lease, Liability, NoncurrentUSD | 44,336,000Source | 35,659,000Source | 37,886,000Source | 19,889,000Source |
| Additional Financial Items | ||||
| Long-term DebtUSD | 54,241,000Source | — | 43,453,000Source | — |
cash flow · annual statements
| Line item | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 11,109,000Source | — | 4,480,000Source | 3,453,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 9,731,000Source | — | 7,380,000Source | 3,854,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | -1,654,000Source | — | 1,705,000Source | 10,236,000Source |
| Increase (Decrease) in InventoriesUSD | -13,533,000Source | — | 14,191,000Source | 988,000Source |
| Increase (Decrease) in Accounts PayableUSD | 7,133,000Source | — | -943,000Source | -608,000Source |
| Deferred Income Tax Expense (Benefit)USD | 113,823,000Source | — | -115,082,000Source | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | 10,952,000Source | — | 9,465,000Source | 31,182,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -31,805,000Source | — | -56,411,000Source | -9,864,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 31,805,000Source | — | 56,411,000Source | 9,864,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 20,067,000Source | — | 3,197,000Source | 112,335,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 38,106,000Source | 60,266,000Source | 126,516,000Source | 170,265,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | 1,670,000Source | 5,000Source |
| Income Taxes Paid, NetUSD | 15,000Source | — | 64,000Source | — |
| Additional Financial Items | ||||
| Amortization of Debt Issuance CostsUSD | 1,503,000Source | — | — | — |
| Deferred Other Tax Expense (Benefit)USD | 118,473,000Source | — | — | — |
| Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber PropertyUSD | -227,000Source | — | -381,000Source | 0Source |
| Gain (Loss) on Disposition of Other AssetsUSD | — | — | — | 0Source |
| Gain (Loss) on Termination of LeaseUSD | — | — | 0Source | 0Source |
| Gain (Loss) on Extinguishment of DebtUSD | -1,865,000Source | — | — | — |
| Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | 11,212,000Source |
| Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | 0Source |
| Income Tax Expense (Benefit)USD | 113,826,000Source | — | -115,011,000Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -140,753,000Source | — | 127,672,000Source | 11,212,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -140,753,000Source | — | 127,672,000Source | 3,318,000Source |
| Operating ExpensesUSD | 25,996,000Source | — | — | — |
| Other Nonoperating Income (Expense)USD | -3,912,000Source | — | — | — |
| Proceeds from Issuance of Common StockUSD | — | — | 0Source | 32,141,000Source |
| Proceeds from Stock Options ExercisedUSD | — | — | 2,700,000Source | 3,600,000Source |
income statement · annual statements
| Line item | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| Total RevenueUSD | 139,911,000Source | 149,266,000Source | 119,597,000Source | 95,868,000Source |
| Cost of RevenueUSD | 132,593,000Source | 117,786,000Source | 82,949,000Source | 66,561,000Source |
| Selling, General and Administrative ExpenseUSD | 25,996,000Source | 27,879,000Source | 21,226,000Source | 17,064,000Source |
| Operating Income (Loss)USD | -18,678,000Source | 3,601,000Source | 15,422,000Source | 12,243,000Source |
| Other Nonoperating Income (Expense)USD | -3,912,000Source | — | — | — |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -26,927,000Source | 1,590,000Source | 12,661,000Source | 11,212,000Source |
| Income Tax Expense (Benefit)USD | 113,826,000Source | 1,331,000Source | -115,011,000Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -140,753,000Source | 259,000Source | 127,672,000Source | 11,212,000Source |
| Earnings Per Share, BasicUSD per share | -2.23Source | 0Source | 2.08Source | 0.06Source |
| Earnings Per Share, DilutedUSD per share | -2.23Source | 0Source | 1.84Source | 0.06Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 63,199,000Source | 62,268,000Source | 61,484,000Source | 58,222,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 63,199,000Source | 63,782,000Source | 70,474,000Source | 59,426,000Source |
| Additional Financial Items | ||||
| Costs and ExpensesUSD | — | 27,879,000Source | 21,226,000Source | 17,064,000Source |
| Current Income Tax Expense (Benefit)USD | 3,000Source | — | — | — |
| Depreciation, Depletion and Amortization, NonproductionUSD | 11,100,000Source | 7,200,000Source | — | — |
| Gross ProfitUSD | 7,318,000Source | 31,480,000Source | 36,648,000Source | 29,307,000Source |
| Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | 11,212,000Source |
| Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | 0Source |
| Interest and Other IncomeUSD | — | — | — | 133,000Source |
| Interest ExpenseUSD | 4,337,000Source | 3,013,000Source | 2,680,000Source | 1,164,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -140,753,000Source | 259,000Source | 127,672,000Source | 3,318,000Source |
| Operating ExpensesUSD | 25,996,000Source | — | — | — |
| Preferred Stock Dividends, Income Statement ImpactUSD | — | 0Source | 0Source | 3,439,000Source |
Filing attachments
ef20042864_ex4-1.htm · 8-K · 2025-02-05
EX-4.1 4 ef20042864_ex4-1.htm EXHIBIT 4.1 Exhibit 4.1 Execution Version AVID BIOSERVICES, INC. AND U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION as Trustee FIRST SUPPLEMENTAL INDENTURE Dated as of February 5, 2025 7.00% Convertible Senior Notes due 2029 FIRST SUPPLEMENTAL INDENTURE, dated as of February 5, 2025 (this “Supplemental Indenture”), among Avid Bioservices, Inc., a Delaware corporation (the “Company”), as issuer, and U.S. Bank Trust Company, National Association, a nation…
Read attachment ↗ef20042864_ex99-1.htm · 8-K · 2025-02-05
EX-99.1 5 ef20042864_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Avid Bioservices poised for significant growth with new partners GHO Capital and Ampersand Capital Partners Acquisition of biologics Contract Development and Manufacturing Organisation Avid Bioservices now completed GHO and Ampersand’s deep experience in CDMO investing to support Avid’s next stage of rapid growth including expanded offerings, talent investment and greater geographic reach London, UK, Boston, MA and Tustin, CA…
Read attachment ↗ef20042864_ex99-2.htm · 8-K · 2025-02-05
EX-99.2 6 ef20042864_ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 Avid Bioservices, Inc. Provides Notice of Fundamental Change and Make-Whole Fundamental Change to Holders of its Convertible Notes in Connection with Completed Merger TUSTIN, Calif., February 5, 2025 - Avid Bioservices, Inc. (“Avid” or the “Company”), a dedicated biologics contract development and manufacturing organization (“CDMO”) working to improve patient lives by providing high quality development and manufacturing services to …
Read attachment ↗ef20042621_ex99-1.htm · 8-K · 2025-01-30
EX-99.1 2 ef20042621_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Avid Stockholders Approve Transaction with GHO and Ampersand Tustin, CA, January 30, 2025 - Avid Bioservices, Inc. (NASDAQ: CDMO) (“Avid” or the “Company”), a dedicated biologics contract development and manufacturing organization (“CDMO”) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that Avid stockholders voted to app…
Read attachment ↗